Two Sigma Investments LP trimmed its position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) by 92.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,633 shares of the company's stock after selling 171,590 shares during the quarter. Two Sigma Investments LP owned approximately 0.07% of Protara Therapeutics worth $72,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Toronto Dominion Bank acquired a new stake in Protara Therapeutics in the 4th quarter valued at $11,030,000. Millennium Management LLC grew its stake in Protara Therapeutics by 2,479.2% in the 4th quarter. Millennium Management LLC now owns 371,453 shares of the company's stock valued at $1,961,000 after acquiring an additional 357,051 shares during the period. Integral Health Asset Management LLC acquired a new stake in Protara Therapeutics in the 4th quarter valued at $7,392,000. J. Goldman & Co LP acquired a new stake in Protara Therapeutics in the 4th quarter valued at $748,000. Finally, Janus Henderson Group PLC acquired a new stake in Protara Therapeutics in the 4th quarter valued at $11,938,000. 38.13% of the stock is owned by hedge funds and other institutional investors.
Protara Therapeutics Price Performance
Shares of NASDAQ:TARA opened at $3.14 on Friday. The firm has a market capitalization of $121.15 million, a PE ratio of -1.11 and a beta of 1.34. The firm's 50-day moving average is $3.49 and its two-hundred day moving average is $4.22. Protara Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $10.48.
Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.18. Analysts expect that Protara Therapeutics, Inc. will post -3.32 EPS for the current fiscal year.
Analyst Ratings Changes
A number of research firms recently issued reports on TARA. Jones Trading raised shares of Protara Therapeutics to a "strong-buy" rating and set a $21.00 price target on the stock in a research note on Thursday, May 22nd. Scotiabank assumed coverage on shares of Protara Therapeutics in a research note on Wednesday, April 16th. They set a "sector outperform" rating and a $12.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $23.00 target price on shares of Protara Therapeutics in a research note on Monday, April 28th. Cantor Fitzgerald assumed coverage on shares of Protara Therapeutics in a research note on Friday, March 14th. They set an "overweight" rating on the stock. Finally, Lifesci Capital assumed coverage on shares of Protara Therapeutics in a research note on Tuesday, March 11th. They set an "outperform" rating and a $22.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $20.50.
Read Our Latest Report on Protara Therapeutics
Insider Activity at Protara Therapeutics
In related news, insider Jacqueline Zummo sold 21,224 shares of the company's stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total value of $96,144.72. Following the completion of the transaction, the insider now directly owns 98,861 shares of the company's stock, valued at $447,840.33. This represents a 17.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 8.40% of the stock is currently owned by corporate insiders.
About Protara Therapeutics
(
Free Report)
Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Protara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.
While Protara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
